Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213757 · ClinicalTrials.gov registry record · Phase 4
Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)
A Phase 4 study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT02213757: Clinical Trial Phase 4 study, sponsored by Medstar Health Research Institute.
NCT02213757 is a Phase 4 study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 29 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02213757, a Phase 4 study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if vaginal estrogen use is associated with resolution of blood in the urine (microscopic hematuria) in postmenopausal women. The hypothesis is that postmenopausal women with blood in the urine (microscopic hematuria) will have higher rates of resolution of hematuria after treatment course with vaginal conjugated equine estrogen cream compared to placebo cream
Primary Outcome
Microscopic urinalysis will be performed after an 8 week trial of vaginal estrogen or placebo. Resolution of microscopic hematuria is defined according to AUA guidelines, \<3 red blood cells per high powered field.
Interventions
- DRUG Placebo vaginal cream
- DRUG Premarin vaginal estrogen cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
Why NCT02213757 stopped before completion
NCT02213757 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo vaginal cream is the first listed.
NCT02213757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02213757 about?
NCT02213757 is a clinical study titled "Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)". The purpose of this study is to determine if vaginal estrogen use is associated with resolution of blood in the urine (microscopic hematuria) in postmenopausal women. The hypothesis is that postmenopausal women with blood in the urine (microscopic hematuria) will have higher rates of resolution of h...
What is the current status of trial NCT02213757?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2014-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02213757?
The interventions under investigation include: Placebo vaginal cream (DRUG), Premarin vaginal estrogen cream (DRUG).
Who is sponsoring clinical trial NCT02213757?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02213757's enrollment target sits among peer trials
29 1634th of 2000 higher than 366 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia